Xeljanz erfaringer ved RA-behandling

I denne delen har vi samlet en rekke videoer fra revmatologkolleger i andre land som har erfaring med å bruke Xeljanz i både kombinasjonsbehandling med metotreksat samt i monoterapi.

Hva sier spesialistene om Xeljanz

Hvorfor ikke lytte til hva dine internasjonale kolleger har å si om Xeljanz? Få deres kommentarer på kliniske studier, virkningen Xeljanz har hatt på deres pasienter og klinisk praksis, inkludert utilstrekkelig respons på metotreksat og hva de anser representerer noen av de største udekkede behov ved RA-behandling.


Rundbordsmøte vedrørende erfaringer med Xeljanz (39:40 min)

Alvin Wells, Janet Pope, Eduardo Mysler and Peter Nash

Round Table Discussion regarding experience with Xeljanz (Lead by Peter Nash):

  • Introduction (00:00 - 01:45)
  • Clinical Experience (01:45 - 04:05)
  • Efficacy and trials (04:05 - 09:16)
  • Mono- and combination therapy (09:16 – 15:33)
  • Laboratory measurements (15:33 – 19:56)
  • Patient Management (19:56 - 26:45)
  • Vaccination (26:45 - 30:59)
  • The ideal XELJANZ patient (30:59 - 34:50)
  • Immunogenicity and GI perforations (34:50 - 37:36)
  • Summary (37:36 - 39:40)

(PP-XEL-NOR-0014)


Peter Nash, 5:25 min

Clinical Experience with Xeljanz:

  • Experience in patients who are inadequate responders to MTX?
  • Which patients can receive Xeljanz?
  • What are your thoughts on the ORAL Standard trial?
  • What do you consider to be the key unmet needs in RA?
  • Which patient types do you prescribe Xeljanz for and why?

(PP-XEL-NOR-0003)


Sergio Schwartzman, 7:25min

Clinical Experience with Xeljanz:

  • Experience in patients who are inadequate responders to MTX?
  • Which patients can receive Xeljanz? - Impact of XELJANZ in your clinical practice and patients?
  • Thoughts on the ORAL Solo and ORAL Standard trials?
  • What do you consider to be the key unmet needs in RA?

(PP-XEL-NOR-0157)


Eduardo Mysler, 8:25 min

Clinical Experience with Xeljanz:

  • Experience in patients who are inadequate responders to MTX?
  • Which patients can receive Xeljanz?
  • Impact of XELJANZ in your clinical practice and patients?
  • Thoughts on the ORAL Solo and ORAL Standard trials?
  • What do you consider to be the key unmet needs in RA?

(PP-XEL-NOR-0002)


Peter Taylor, 3:32 min

Unmet Need in RA

  • Is there nothing left to do in RA?
  • How many patients actually achieve their treatment goals?
  • What proportion of patients fail methotrexate?
  • What is the impact of biologic monotherapy?
  • How important is the route of administration?

(PP-XEL-NOR-0006)

 

Les mer om Xeljanz og behandling av RA:

 

Referanser:

  • Xeljanz SPC, 08.11.2018
  • Methotrexate SPC, 09.08.2018
  • Fleischmann R, Kremer J, Cush J et al. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis, N Engl J Med 2012;367:495–507
  • van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis, N Engl J Med 2012;367:508–19